The unfinished part of the pandemic treaty is now back on the table
Negotiators gathered in Geneva on April 27 for an extra week of talks to settle the last unresolved piece of the World Health Organization’s pandemic agreement: how countries will share pathogens with pandemic potential and how the benefits that come from that sharing, including vaccines, tests, and treatments, will be distributed.
The issue is technically known as the Pathogen Access and Benefit-Sharing system, or PABS. In practice, it goes to the core of a question that shaped global anger during COVID-19: if countries contribute the biological data and samples needed to develop lifesaving tools, what guarantees do they have that they will gain fair access to the resulting products when a crisis hits?
Why this final mechanism matters so much
The broader treaty was adopted by WHO members in May 2025 after more than three years of negotiations. It was meant to improve coordination, surveillance, and access during future health emergencies and avoid a repeat of the fractured international response seen during the coronavirus pandemic. But the most politically sensitive element was left unfinished.
That omission was not minor. The supplied source text describes PABS as the heart of the treaty. Without it, the agreement risks becoming an ambitious framework without a settled mechanism for one of the most contentious real-world exchanges in global health: rapid pathogen sharing in return for meaningful, equitable benefits.
WHO Director-General Tedros Adhanom Ghebreyesus opened the talks with a blunt warning. The world, he said, cannot afford to lose the opportunity and remain unprepared for the next pandemic. The message reflects a familiar but still unresolved tension. Countries broadly agree on the need for readiness, yet they remain divided over the commitments that readiness requires.
The central divide: trust, fairness, and incentives
According to the source material, wealthy countries and developing nations remain at loggerheads. Developing countries fear they will once again be asked to share viruses or other pathogen data without firm guarantees that vaccines and treatments will reach them equitably in a future emergency. That mistrust is rooted in lived experience. Many countries, especially in Africa, felt left behind during the scramble for COVID-19 vaccines.
On the other side, some countries are asking whether pharmaceutical companies will have the capacity and motivation to participate meaningfully in a pandemic framework without a clearer return on investment. WHO Chief Scientist Sylvie Briand summarized the stand-off by saying that “blame is shared,” reflecting the fact that both political trust and industrial incentives are in play.
This is what makes PABS difficult. It is not simply a diplomatic text problem. It is an attempt to encode fairness, speed, sovereignty, and commercial reality into a single operating system for crisis response. Those goals do not naturally align.
What is at stake in the Geneva week
The timeline is tight. Countries have until Friday to negotiate a PABS outcome that can be approved during the World Health Assembly, which opens May 18. That creates pressure for compromise, but not necessarily confidence that one will be reached. The source text describes progress as slow and says compromise will be “very hard,” though one diplomat suggested the European Union was making an effort to show more flexibility.
That hint matters because movement by major blocs can determine whether a multilateral health agreement survives the final stretch. Yet even if a deal is reached, the substance will be closely scrutinized. A weak arrangement could be criticized for institutionalizing imbalance. A strong one could trigger concerns from governments or industry actors worried about obligations and costs.
In that sense, Geneva is not only deciding whether there will be a PABS mechanism. It is also deciding what kind of precedent the world wants for future outbreaks: a solidarity model with stronger expectations of equity, or a looser arrangement that relies more heavily on goodwill and ad hoc bargaining.
The COVID lesson still drives the politics
Much of the urgency around these talks comes from the memory of what happened when the last pandemic upended global systems. COVID-19 exposed how quickly international cooperation can give way to competition when vaccines, tests, and treatments become scarce. Countries with manufacturing capacity or purchasing power moved first. Others waited.
The treaty effort was supposed to address that breakdown, but it was always clear that agreement on principles would be easier than agreement on distribution. Pathogen sharing can sound abstract, yet it has immediate implications for national sovereignty, scientific access, public health preparedness, and the commercial pipelines of global drugmakers.
That is why developing countries continue to push for stronger guarantees. From their perspective, participation without enforceable benefit-sharing risks repeating the same pattern under a more polished legal framework.
Why this negotiation reaches beyond health ministries
The outcome will matter not just to health officials, but also to researchers, biotech developers, manufacturers, and governments managing both diplomatic and industrial policy. A functioning pathogen-sharing system affects how quickly samples move, how rapidly countermeasures can be designed, and how legitimacy is maintained when those countermeasures are deployed.
If countries do not trust the system, they may hesitate to share quickly during an emergency. That hesitation could slow surveillance and response at the exact moment speed matters most. In other words, the treaty’s unresolved issue is not peripheral. It directly affects whether the next global alert begins with cooperation or suspicion.
The likely test of success
The real measure of any Geneva outcome will be whether countries that felt sidelined during COVID-19 believe the new framework materially changes their position. A deal that is merely functional on paper but politically unconvincing could still leave the system brittle. By contrast, an agreement seen as both fair and workable might strengthen the legitimacy of the entire pandemic architecture.
The WHO leadership has made clear that perfection is not the standard. Tedros said no agreement ever is. But the harder question is whether negotiators can produce one that is fair enough to rebuild trust and practical enough to survive the next crisis.
That is what this week is really about. Not whether the world supports preparedness in theory, but whether it can agree on the rules of solidarity before the next emergency forces the question again.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
